Insights
Unlocking the Potential of Genetic Medicines with Anti-Silencing DNA Technology | Executive Summary & White Paper
Discover how Houdini Bio is overcoming cellular gene silencing, a fundamental constraint limiting genetic medicine performance. Learn how our AI-powered ARCANA platform redesigns therapeutic DNA for stronger, longer-lasting expression, and explore the scientific and commercial opportunities enabled by more durable, lower-dose, cost-effective therapies through our executive summary and white paper.
Read Full Insight
.png)
Houdini Bio Launches to Solve the Therapeutic and Commercial Bottlenecks of Genetic Medicines
Houdini Bio today announced its official launch, having surpassed key milestones supported by approximately £1.5 million in non-dilutive grant funding and capital from an oversubscribed pre-seed round led by SCVC (the venture arm of Science Creates), with participation from Deep Science Ventures and the University of Cambridge (Cambridge Enterprise VC).
Read Full Insight